Cite
HARVARD Citation
Fraser, G. et al. (2020). Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia & lymphoma. 61 (13), pp. 3188-3197. [Online].